SEARCH

SEARCH BY CITATION

References

  • 1
    World Health Organization. Hepatitis B. Fact sheet no. 204. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed September 14, 2011.
  • 2
    Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005; 34: 1329-1339.
  • 3
    Taylor BC, Yuan JM, Shamliyan TA, Shaukat A, Kane RL, Wilt TJ. Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: a systematic review of evidence. HEPATOLOGY 2009; 49( 5 Suppl.): S85-S95.
  • 4
    Chen CJ, Yang HI, Iloeje UH; REVEAL-HBV Study Group. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. HEPATOLOGY 2009; 49( 5 Suppl.): S72-S84.
  • 5
    Jonas MM, Block JM, Haber BA, Karpen SJ, London WT, Murray KF, et al. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. HEPATOLOGY 2010; 52: 2192-2205.
  • 6
    Haber BA, Block JM, Jonas MM, Karpen SJ, London WT, McMahon BJ, et al. Recommendations for screening, monitoring, and referral of pediatric chronic hepatitis B. Pediatrics 2009; 124: e1007-e1013.
  • 7
    Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DKH, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139: 1218-1229.
  • 8
    Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-2455.
  • 9
    Marcellin P, Heathcote E, Corsa A, Liu Y, Miller MD, Kitrinos KM. No detectable resistance to tenofovir disoproxil fumarate (TDF) following up to 240 weeks of treatment in patients with HBeAg+ and HBeAg− chronic hepatitis B virus infection. Presented at: Annual Meeting of the American Association for the Study of Liver Diseases; November 4-8, 2011; San Francisco, CA. Abstract 238.
  • 10
    Zhu Y, Curtis M, Borroto-Esoda K. HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A-H and its use in antiviral phenotyping assays. J Virol Methods 2011; 173: 340-346.
  • 11
    van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. HEPATOLOGY 2010; 51: 73-80.
  • 12
    Jonas MM, Kelley DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002; 346: 1706-1713.
  • 13
    Sokal EM, Kelly DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. HEPATOLOGY 2006; 43: 225-232.
  • 14
    Feld JJ, Heathcote EJ. Hepatitis B e antigen-positive chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006; 26: 116-129.
  • 15
    Staples B, Bravender T. Drug compliance in adolescents: assessing and managing modifiable risk factors. Pediatr Drugs 2002; 4: 503-513.
  • 16
    Gill US, Al-Shamma S, Burke K, Ross V, Marley R, Kooner P, et al. Factors determining bone mineral density loss in chronic hepatitis B patients: is tenofovir disoproxil fumarate the main culprit? Gut 2011; 60( Suppl. 1): A230.